Cross-reactivity conferred by homologous and heterologous prime-boost a/h5 influenza vaccination strategies in humans: A literature review

Adinda Kok, Ron A.M. Fouchier, Mathilde Richard*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

3 Citations (Scopus)
22 Downloads (Pure)


Avian influenza viruses from the A/H5 A/goose/Guangdong/1/1996 (GsGd) lineage pose a continuing threat to animal and human health. Since their emergence in 1997, these viruses have spread across multiple continents and have become enzootic in poultry. Additionally, over 800 cases of human infection with A/H5 GsGd viruses have been reported to date, which raises concerns about the potential for a new influenza virus pandemic. The continuous circulation of A/H5 GsGd viruses for over 20 years has resulted in the genetic and antigenic diversification of their hemagglutinin (HA) surface glycoprotein, which poses a serious challenge to pandemic preparedness and vaccine design. In the present article, clinical studies on A/H5 influenza vaccination strategies were reviewed to evaluate the breadth of antibody responses induced upon homologous and heterologous primeboost vaccination strategies. Clinical data on immunological endpoints were extracted from studies and compiled into a dataset, which was used for the visualization and analysis of the height and breadth of humoral immune responses. Several aspects leading to high immunogenicity and/or cross-reactivity were identified, although the analysis was limited by the heterogeneity in study design and vaccine type used in the included studies. Consequently, crucial questions remain to be addressed in future studies on A/H5 GsGd vaccination strategies.

Original languageEnglish
Article number1465
Issue number12
Publication statusPublished - 10 Dec 2021

Bibliographical note

Funding Information:
The research of A.K., M.R. and R.A.M.F. was funded by Biomedical Advanced Research and Authority (BARDA) contract HHSO100201500033C and is funded by NIAID/NIH contract number 75N93021C00014.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


Dive into the research topics of 'Cross-reactivity conferred by homologous and heterologous prime-boost a/h5 influenza vaccination strategies in humans: A literature review'. Together they form a unique fingerprint.

Cite this